Benefits of Alzheimer’s drug Leqembi persist when treatment is halted, trial shows
By
Alicia Lasek
Apr 09, 2023
A relative slowing of cognitive decline continues for up to two years in patients who stop taking the recently authorized drug, clinical trial data reveal.
CMS restricts coverage of Alzheimer’s drug Aduhelm to clinical trials
By
Alicia Lasek
Apr 08, 2022
Coverage of aducanumab (Aduhelm) is officially limited to clinical trials only, the agency announced Thursday. Most stakeholders have called for restricted use while more efficacy and safety data is gathered,...